| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
* From the Department of Anaesthesia,
the Department of Surgery, Division of Cardiac Surgery,
and the Department of Medicine, Division of Hematology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada.
Address correspondence to: Dr. Viren N. Naik, Department of Anaesthesia, St. Michael’s Hospital, University of Toronto, 30 Bond Street Toronto, Ontario M5B 1W8, Canada. Phone: 416-864-5071; Fax: 416-864-6014; E-mail: naikv{at}smh.toronto.on.ca
Purpose: To describe a case of persistent and excessive bleeding following an aortic valve and ascending aorta replacement that was successfully managed with recombinant factor VIIa (rFVIIa). The postulated mechanisms for rFVIIa are discussed.
Clinical features: A 75-yr-old female with no preoperative coagulopathy underwent a tissue aortic valve replacement and supracoronary ascending aorta replacement for severe aortic stenosis and an ascending aortic aneurysm. Following surgery, she bled in excess of 200 mL•hr-1 despite a nearly normal platelet count and nearly normal coagulation parameters. The patient was surgically re-explored twice in seven hours, and despite the presence of near normal in vitro coagulation parameters, the patient continued to bleed. Multiple units of fresh frozen plasma, platelets and cryoprecipitate were administered empirically. We then administered a single 6-mg (107 µg•kg-1) iv dose of rFVIIa. Following the administration of rFVIIa, blood loss decreased to a total of 440 mL over the next 12 hr.
Conclusions: This case describes the use of rFVIIa for intractable bleeding postcardiovascular surgery in the presence of nearly normal laboratory markers of coagulation. Further controlled laboratory and clinical studies are required to define the role of rFVIIa in patients undergoing cardiovascular surgery.
This article has been cited by other articles:
 |
|
 |
|
  S. Dunkley, L. Phillips, P. McCall, J. Brereton, R. Lindeman, G. Jankelowitz, and P. Cameron Recombinant Activated Factor VII in Cardiac Surgery: Experience From the Australian and New Zealand Haemostasis Registry Ann. Thorac. Surg., March 1, 2008; 85(3): 836 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Mazer, H. Leong-Poi, J. Mahoney, D. Latter, B. H. Strauss, and J. M. Teitel Vascular Injury and Thrombotic Potential: A Note of Caution About Recombinant Factor VIIa Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 261 - 264. [Abstract] [PDF]
|
|
|
|
 |
|
 S. J. Johnson, M. B. Ross, and K. G. Moores Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery Am. J. Health Syst. Pharm., September 1, 2007; 64(17): 1808 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Warren, K. Mandal, V. Hadjianastassiou, L. Knowlton, S. Panesar, K. John, A. Darzi, and T. Athanasiou Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review Ann. Thorac. Surg., February 1, 2007; 83(2): 707 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Romagnoli, S. Bevilacqua, S. Gelsomino, S. Pradella, L. Ghilli, C. Rostagno, G. F. Gensini, and C. Sorbara Small-Dose Recombinant Activated Factor VII (NovoSeven(R)) in Cardiac Surgery. Anesth. Analg., May 1, 2006; 102(5): 1320 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ballen, M. Raabe, and B. Muirhead Aortic dissection and hypothermic arrest in a Jehovah's Witness patient: a case for recombinant factor VIIa?: [Dissection aortique et asystolie sous hypothermie chez un Temoin de Jehovah : un cas pour le facteur VIIa recombinant ?]. Can J Anesth, April 1, 2006; 53(4): 353 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Brenner, R. Hoffman, D. Balashov, E. Shutluko, S. Culic, and E. Nizamoutdinova Control of Bleeding Caused by Thrombocytopenia Associated With Hematologic Malignancy: An Audit of the Clinical Use of Recombinant Activated Factor VII Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 401 - 410. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Hyllner, E. Houltz, and A. Jeppsson Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery Eur. J. Cardiothorac. Surg., August 1, 2005; 28(2): 254 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Raivio, R. Suojaranta-Ylinen, and A. H. Kuitunen Recombinant Factor VIIa in the Treatment of Postoperative Hemorrhage After Cardiac Surgery Ann. Thorac. Surg., July 1, 2005; 80(1): 66 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. DiDomenico, M. G. Massad, J. Kpodonu, R. A. Navarro, and A. S. Geha Use of Recombinant Activated Factor VII for Bleeding Following Operations Requiring Cardiopulmonary Bypass Chest, May 1, 2005; 127(5): 1828 - 1835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Canadian Anesthesiologists' Society Annual Meeting: Award-Winning Abstracts Can J Anesth, December 1, 2004; 51(10): A1 - A10. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D Flynn, M. Pajoumand, P. C Camp Jr, M S. Jahania, C. Ramaiah, and W. S Akers Recombinant Factor VIIa for Refractory Bleeding Following Orthotopic Heart Transplantation Ann. Pharmacother., October 1, 2004; 38(10): 1639 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Stratmann, A. M. deSilva, E. E. Tseng, J. Hambleton, M. Balea, A. J. Romo, M. J. Mann, N. L. Achorn, W. F. Moskalik, and C. W. Hoopes Reversal of Direct Thrombin Inhibition After Cardiopulmonary Bypass in a Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., June 1, 2004; 98(6): 1635 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Chhina, H. Lapierre, Z. S. Jackson, H. M. Leong-Poi, J. M. Teitel, D. A. Latter, B. H. Strauss, P. L. Gross, and C. D. Mazer Effect of Recombinant Factor VIIa on Rabbit Vascular Graft Patency Can J Anesth, June 1, 2004; 51(suppl_1): A1 - A1. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
